Effects of glucose-lowering agents on ischemic stroke

Avgerinos, Konstantinos I.; Τζιόμαλος, Κωνσταντίνος

doi:10.4239/wjd.v8.i6.270

Cited by 4 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past few years, several large cardiovascular outcome trials employing GLP-1R agonists and DPP-4i in human subjects with T2D at increased cardiovascular risk have been concluded (reviewed by Nauck et al [ 5 ], Avgerinos and Tziomalos [ 6 ] and Hemmingsen et al [ 7 ]). For the GLP-1R agonists, some of these studies have shown reduced cardiovascular mortality (LEADER employing liraglutide [ 8 ]) and stroke incidence (SUSTAIN-6, employing semaglutide [ 9 ]).…”

mentioning

confidence: 99%

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Darsalia

Larsson

Klein

et al. 2018

Cardiovasc Diabetol

View full text Add to dashboard Cite

mentioning

confidence: 99%

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Darsalia

Larsson

Klein

et al. 2018

Cardiovasc Diabetol

View full text Add to dashboard Cite

“…Несмотря на то что гипергликемия в остром периоде ИИ ассоциируется с неблагоприятным его прогнозом независимо от наличия СД, пока нет уверенности, что применение инсулина способствует улучшению исхода ИИ [18]. Кроме того, влияние инсулина на снижение риска развития геморрагического компонента в инфаркте мозга и тяжесть течения ИИ пока не доказана [19].…”

unclassified

Type 2 diabetes mellitus in patients with acute ischemiс stroke is associated with a decrease in plasma glutathione levels

Maksimova

Иванов

Nikiforova

et al. 2020

РНЖ

View full text Add to dashboard Cite

Ischemic stroke (IS) and type 2 diabetes mellitus are factors that aﬀect the homeostasis of low-molecularweight aminothiols (cysteine, homocysteine, glutathione etc.). It has already been shown that IS in the acute period led to a decrease a level of reduced forms of aminothiols, but it is not clear whether type 2 diabetes mellitus has a noticeable eﬀect there. Objective: to reveal the features of homeostasis of aminothiols in patients with type 2 diabetes mellitus in acute IS. Material and methods. The study involved 76 patients with primary middle cerebral artery IS in the first 10–24 hours after development of neurological symptoms. Group 1 included 15 patients with IS and type 2 diabetes mellitus, group 2 — 61 patients with IS and stress hyperglycemia. Their total plasma levels of cysteine, homocysteine, and glutathione, their reduced forms, and redox status were determined at admission (in the first 24 hours after IS). Results. There was a decrease in the level of total glutathione level (1.27 vs. 1.65 μM, p = 0.021), as well as its reduced form (0.03 vs. 0.04 μM, p = 0.007) in patients with IS and type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who had a low redox status of homocysteine (0.65–1.2%) and glutathione (0.7–2.0%) were also characterized by a decrease in total glutathione level (p = 0.02; p = 0.03). Conclusion. Thus, type 2 diabetes mellitus is associated with a decrease in the level of total glutathione in acute IS. Probably, type 2 diabetes mellitus is characterized by a particular relationship between the metabolism of homocysteine, glutathione and glucose. Therefore, the search for homocysteine-dependent approaches to correct glutathione metabolism in type 2 diabetes mellitus may be of interest as an adjuvant therapy for IS.

show abstract

Effects of GLP-1 receptor agonists on neurological complications of diabetes

García-Casares,

González-González,

de la Cruz-Cosme

et al. 2023

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy. Semaglutide subcutaneous and dulaglutide reduced stroke cases. Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events. Exenatide, dulaglutide and liraglutide improved general cognition but no significant effect on diabetic peripheral neuropathy has been reported with GLP-1 RAs. GLP-1 RAs are promising drugs that seem to be useful in the reduction of some neurological complications of diabetes. However, more studies are needed.

show abstract

Effects of glucose-lowering agents on ischemic stroke

Cited by 4 publications

References 82 publications

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Type 2 diabetes mellitus in patients with acute ischemiс stroke is associated with a decrease in plasma glutathione levels

Effects of GLP-1 receptor agonists on neurological complications of diabetes

Contact Info

Product

Resources

About